ACEPODIA Trademark

Trademark Overview


On Thursday, June 15, 2023, a trademark application was filed for ACEPODIA with the United States Patent and Trademark Office. The USPTO has given the ACEPODIA trademark a serial number of 98044259. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, November 26, 2024. This trademark is owned by Acepodia Biotechnologies Ltd.. The ACEPODIA trademark is filed in the Pharmaceutical Products category with the following description:

Biological preparations for use in cell cultures for medical or therapeutic purposes; Biological tissue cultures for medical purposes; Medicinal preparations for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases for human purposes; Drugs, namely, pharmaceuticals for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases for medical purposes; Pharmaceutical preparations for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases; Cells for clinical, medical, veterinary, or therapeutic purposes or use; C...
acepodia

General Information


Serial Number98044259
Word MarkACEPODIA
Filing DateThursday, June 15, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, November 26, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 16, 2024

Trademark Statements


Goods and ServicesBiological preparations for use in cell cultures for medical or therapeutic purposes; Biological tissue cultures for medical purposes; Medicinal preparations for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases for human purposes; Drugs, namely, pharmaceuticals for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases for medical purposes; Pharmaceutical preparations for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases; Cells for clinical, medical, veterinary, or therapeutic purposes or use; Cell-derived preparations, namely, natural killer cell, gamma delta T cell, or other immune cell-derived preparations, for clinical, medical, veterinary, or therapeutic purposes; Therapeutic products derived from cells or cell-derived preparations, namely, natural killer cells, gamma delta T cell, and other immune cell, for clinical, medical, veterinary, or therapeutic purposes; Kits comprised of cells and reagents and also containing related instructions for clinical, medicinal, veterinary, or therapeutic purposes or use; Kits comprised of cell-derived preparations, namely, natural killer cell, gamma delta T cell, and other immune cell-derived preparations and reagents and also containing related instructions, for clinical, medicinal, veterinary, or therapeutic purposes or use; Gene therapy products, namely, genetically engineered cells for medical or clinical purposes or use; Pharmaceutical preparations, pharmaceutical products, therapeutic agents, and pharmaceuticals for targeting tissues based on select tissue markers and ligands, or for the purpose of binding ligands using engineered proteins and receptors; Pharmaceuticals, namely, pharmaceutical preparations, pharmaceutical products, therapeutic agents, and pharmaceuticals for use in the prevention and treatment of cancer, tumors, hematologic disease, solid cancers, hyperproliferative disease, autoimmune disease, neuronal diseases, hematopoietic cell-related diseases, metabolic syndrome, infectious diseases, immune disease or disorder, and inflammation and inflammatory diseases and in cellular transplants; Biotechnology and pharmaceutical products, namely, therapeutic cells, therapeutic peptide, therapeutic proteins, and therapeutic nucleic acids for human use for the treatment and prevention of cancer, tumors, autoimmune disease, a neuronal disease, a hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases; Pharmaceutical preparations or pharmaceutical products, namely, cell media for use in activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers; Pharmaceutical preparations, biological preparations, and therapeutic agents to modulate cell function or cell fate; Reagents for medical research, pharmaceutical drug discovery and development, pre-clinical, clinical, and medical use; Biological preparations and therapeutic agents used for medical cell therapy, adoptive immunotherapy, or other immunotherapy; Therapeutic cell preparation based on NK cells (natural killer cells), gamma delta T cell, other immune cell, or other cell for the treatment of cancer, tumors, neuronal diseases, hematopoietic cell-related diseases, metabolic syndrome, infectious diseases, auto-immune diseases, and inflammatory and immune disorders; Bio-engineered component for a therapeutic material, namely, cell lines based on NK cells (natural killer cells), gamma delta T cell, or other immune cell used for medical or clinical use used for immunotherapy

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 19, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAcepodia Biotechnologies Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew Taipei City 22175
TW

Party NameAcepodia Biotechnologies Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew Taipei City 22175
TW

Trademark Events


Event DateEvent Description
Monday, June 19, 2023NEW APPLICATION ENTERED
Wednesday, July 19, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 5, 2024ASSIGNED TO EXAMINER
Friday, March 8, 2024EXAMINERS AMENDMENT -WRITTEN
Friday, March 8, 2024EXAMINERS AMENDMENT E-MAILED
Friday, March 8, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, March 8, 2024EXAMINER'S AMENDMENT ENTERED
Friday, March 8, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 16, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 16, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, March 27, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 11, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 26, 2024SOU EXTENSION 1 FILED
Tuesday, November 26, 2024SOU EXTENSION 1 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 26, 2024SOU TEAS EXTENSION RECEIVED